Clinical Trial

A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the safety and tolerability of SHR-4506 Injection in patients with malignant tumors and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-07; most recent amendment 2026-05-14.
Status change: Not Yet Recruiting → Recruiting 2025-08-15
Trial Details
NCT Number NCT07068932
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Malignant Tumors of Adults
Enrollment 102 participants
Start Date 2025-07-22
Primary Completion 2027-02 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-05-18